This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More
by Zacks Equity Research
Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.
Is a Beat Likely for AstraZeneca (AZN) in Q1 Earnings?
by Zacks Equity Research
AstraZeneca's (AZN) first-quarter results are expected to reflect the impact of strong demand for new drugs as well as coronavirus-led disruption. Investors are likely to focus on COVID-19 vaccine related updates.
Stocks Have First Down Week in Five on Tax Hike Fears
by David Borun
Stocks fall after a proposed rise in capital gains taxes, but make up most of the lost ground with a Friday rally.
Merck (MRK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
Will Strong Veklury and HIV Sales Aid Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports first-quarter 2021 results.
Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter
by Zacks Equity Research
Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $78.57, moving +1.17% from the previous trading session.
Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 2021.
J&J (JNJ) Q1 Earnings Top, COVID-19 Vaccine Brings $100M Sales
by Zacks Equity Research
J&J (JNJ) beats first-quarter 2021 estimates for both earnings and sales. It boosts quarterly dividend by 5%.
Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.
Merck (MRK) Stops MK-7110 Development, Focuses on Molnupiravir
by Zacks Equity Research
Merck (MRK) will start evaluating oral molnupiravir in non-hospitalized COVID-19 patients in a late-stage study. It stops MK-7110 development due to requirement of additional studies.
Pharma Stock Roundup: JNJ's COVID-19 Vaccine Woes, MRK Ends COVID-19 Drug Development
by Kinjel Shah
FDA & CDC temporarily halt J&J's (JNJ) COVID-19 vaccine use. Merck (MRK) ends development of COVID-19 drug.
Will Solid Pharma Unit Performance Drive J&J (JNJ) Q1 Earnings?
by Zacks Equity Research
In J&J's (JNJ) Pharma segment, its oncology drugs, Imbruvica and Darzalex as well as psoriasis treatment drug, Stelara, are likely to have driven sales growth.
Bristol Myers' (BMY) Opdivo Combo Gets EU Nod for First-Line RCC
by Zacks Equity Research
The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Cabometyx for first-line treatment of advanced renal cell carcinoma.
Merck (MRK) Stock Moves -0.04%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $76.40, moving -0.04% from the previous trading session.
The Zacks Analyst Blog Highlights: Home Depot, Toyota, International Business Machines, Merck and CVS Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, Toyota, International Business Machines, Merck and CVS Health
Top Research Reports for Home Depot, Toyota & IBM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot (HD), Toyota Motor (TM), and International Business Machines (IBM).
Bristol Myers' (BMY) Opdivo Combo Encouraging in NSCLC study
by Zacks Equity Research
Bristol Myers Squibb (BMY) announces positive results from a late-stage study evaluating Opdivo plus chemotherapy for resectable NSCLC.
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study
by Zacks Equity Research
Bristol Myers (BMY) announces encouraging data from the late-stage study evaluating Opdivo plus chemotherapy and Opdivo plus Yervoy in ESCC study.
Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer Study
by Zacks Equity Research
Merck (MRK) is developing a Keytruda monotherapy regimen for adjuvant treatment of renal cell carcinoma patients.
Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes
by Kinjel Shah
FDA delays decision on Pfizer (PFE), AbbVie (ABBV) and Lilly's (LLY) filings for JAK inhibitor candidates. AstraZeneca's (AZN) COVID-19 vaccine troubles continue.
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised)
by Zacks Equity Research
Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $75.49, marking a -0.83% move from the previous day.